RNARevive is on a hot streak that includes participation in Plug and Play's Lifetech Batch 2. The company develops self-amplifying RNA therapies for age-related diseases, with an emphasis on bone health. Self-amplifying RNA therapies can reduce how much medication a patient needs by stimulating healing processes in the body. "Instead of manufacturing therapeutic proteins outside the body, we deliver a temporary RNA instruction that enables a patient's own cells to produce the medicine," the company wrote. "Because the RNA is self-amplifying, a small dose can drive therapeutic protein production over a longer period of time."
Innovators from RNARevive will travel to Indianapolis and Silicon Valley during the spring session of the Plug and Play Lifetech program. The accelerator is a partnership with academic institutions and healthcare providers in Indiana, including Indiana University Health, the state's largest healthcare system. It culminates in an expo and final showcase on June 3. This follows RNARevive's 2025 receipt of an Innovation Catalyst Grant, an entrepreneurial fellowship to help recent STEM graduates develop and commercialize innovative products and services with a hardware component.
UCeed's Founder Matching Program highlighted the match it made between RNARevive founder Mardin (Asghar) Fallah and Nina Karpoff, who now serves as the company's director of business development. Karpoff's mix of science and business experience includes co-founding retail brand Good Goods Co., while Fallah is an adjunct assistant professor in medical genetics at the University of Alberta, in addition to being CEO of the company he started.